Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia
Journal of Thrombosis and Haemostasis · 2026-11 · 24 (11) · 4070-4075
DOI: 10.1016/j.jtha.2026.07.024 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2026-11. Verfasst von Elizabeth B Caudill und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: ecaudill@bwh.harvard.edu. Hauptthemen laut MEDLINE: Heparin, Thrombocytopenia, Anticoagulants. Die Arbeit nennt 12 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVE: To evaluate heparin re-exposure practices and safety in patients with prior HIT. BACKGROUND: Heparin-induced thrombocytopenia (HIT)-associated antibodies are transient, often declining to undetectable levels within approximately 3 to 6 months. Therefore, patients with a remote history of HIT are unlikely to retain immune memory to heparin. METHODS: This single-center retrospective study evaluated patients with prior HIT admitted between October 1, 2018, and September 30, 2024. HIT was defined as a positive serotonin-release assay result; positive platelet factor 4 immunoassay result with optical density ≥0.4 units or latex immunoturbidimetric assay ≥1 units/mL in the absence of serotonin-release assay and treated as having HIT; or documented diagnosis. The major outcome of this study was incidence of HIT recurrence in patients with a history of HIT who were re-exposed to heparin products on a subsequent admission. Minor outcomes included time from HIT diagnosis to heparin re-exposure, time from re-exposure to HIT recurrence, and incidence of in-hospital mortality, thrombotic event(s), or bleeding event(s) during a recurrent HIT episode. RESULTS: Of the 35 patients who were re-exposed to heparin products, 1 (2.9%) developed recurrent HIT after 9 days of treatment with intravenous unfractionated heparin, without associated in-hospital mortality, thrombosis, or bleeding. Median time from first HIT diagnosis to heparin re-exposure was 8.1 years (IQR, 2.7-14.2 years). CONCLUSION: These findings suggest that re-exposure to heparin products in patients with a remote history of HIT may be a safe option for patients requiring parenteral anticoagulation, given the low incidence of HIT recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: ecaudill@bwh.harvard.edu.
- Department of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts, USA.
- Hematology Division, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Zitieren
APA
Caudill, E. B., Kim, J. H., Kanaan, D. M., Sylvester, K. W., Pimentel, L. Y., Kim, C. S., & Connors, J. M. (2026). Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis, 24(11), 4070-4075. https://doi.org/10.1016/j.jtha.2026.07.024
Vancouver
Caudill EB, Kim JH, Kanaan DM, Sylvester KW, Pimentel LY, Kim CS, et al. Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia. Journal of Thrombosis and Haemostasis. 2026;24(11):4070-4075. doi:10.1016/j.jtha.2026.07.024
BibTeX
@article{Caudill2026,
author = {Caudill, Elizabeth B and Kim, Ju Hee and Kanaan, Dareen M and Sylvester, Katelyn W and Pimentel, Liriany Y and Kim, Christine S and Connors, Jean M},
title = {Heparin re-exposure in patients with a history of heparin-induced thrombocytopenia},
journal = {Journal of Thrombosis and Haemostasis},
year = {2026},
volume = {24},
number = {11},
pages = {4070--4075},
doi = {10.1016/j.jtha.2026.07.024}
}
EUVIMED